N&PD Moderators: Skorpio
D-Deprenyl
overstoned
Greenlighter
This looks like an awesome one. Probably a lot less peripheral effects than l-deprenyl. Hmm, I wonder why?
Why hasn't it popped up anywhere?
sekio
Bluelight Crew
D-deprenyl is habit forming, L- is not, and ironically it looks like the L- isomer is less prone to side effects, because L-amphetamine at low doses is basically inactive - making it a more selective MAO-B inhibitor over the D isomer.
I don't doubt that it is habit forming (necessarily) but I was under the impression that the the concentration of amphetamine would still be too low; ipso facto: can you source that?
Also I don't mean to derail the thread but could you give a rough estimate in percentage of how much of L-deprenyls effect is due to l-methamphetamine/amphetamine?
Jabberwocky
Frumious Bandersnatch
There's so many reasons a compound is/isn't popular.. IMO, the l isomer should be far more popular than it is. But isomers (gah I cannot recall if l or d) have popped up in E pills before.
This looks like an awesome one. Probably a lot less peripheral effects than l-deprenyl. Hmm, I wonder why?
Why hasn't it popped up anywhere?
Am also very interested in this and never found a good answer... in threads here I've seen much difficulty determining the %'s of amp's actions in terms of transporter versus agonism effects, so when discussing amp that's from pro-drug that's also MAOi, I doubt we'll get anything concrete :/
Last edited by a moderator:
ebola?
Bluelight Crew
Polarity (well, "polarness") doesn't vary by stereoisomer.
oops
Of deprenyl? I doubt it.
Amphetamine exerts only very minor direct agonism at any dopamine receptor subtype.
ebola
Last edited:
endotropic
Bluelight Crew
He said popular not polar you goof :D
I searched pubmed pretty hard last time you asked this question and I couldn't find anything useful. The FDA might have some metabolic information in their approval documentation, that would be the next place to look I think.
Jabberwocky
Frumious Bandersnatch
I meant 'in terms of DAT reversal versus crossing into cell', that's my bad. But I've never seen a good 'guesstimate' at proportions of effect based on the actions that way and, in terms of deprenyl, it'd be skewed because maob wouldn't be (as)active.
And I've never tested pills but just googling 'ecstasy pills selegeline' seems to indicate "sitting duck" pills had them (not worth researching/verifying, but it would be a pretty logical inclusion if you were the type who'd think it okay to mislabel products, ie the majority of pill-stampers out there 
sekio
Bluelight Crew
Lightning-Nl
Bluelighter
There is actually significant evidence that Amphetamine is anti-addictive when taken in strictly therapeutic dosages. For instance - people with ADHD are at an insanely higher risk of having an addiction to Nicotine at some point in their lives (it's something like 60% if I remember correctly). However, ADHD patients who are treated with stimulant drugs (the study I'm remember specifically used Methylphendiate - Ritalin) drops that likelihood to BELOW the likelihood someone without ADHD not on these meds has...
ebola?
Bluelight Crew
This is likely because presentation of ADD symptoms makes individuals predisposed toward addictive behavior.
ebola
Jabberwocky
Frumious Bandersnatch
source? am not trying to 'call out' but really, really interested in this for personal reasons and never come across this ever.
/BTW, have read your thread on TAAR, wrt trace amine pharmaco's, many times, and have many things to say/add, but just not finished w/ my reply yet (am fully aware of when you wrote it; I'd been finished playing w/ raw pea for weeks when I read it and am still trying to formulate some type of 'trip report' / writeup on the subject.. It's actually at that point now, coincidentally (monday @latest), but that'll be a different thread for b-pea raw itself, i actually have some things to add to your thread on its main receptor TAAR as well. Thnx for that thread and hope you can clarify what you said above!
Lightning-Nl
Bluelighter
Just go the Wikipedia article on Amphetamine. The first section below the intro (Uses - Medical) is filled with a plethora of studies on the subject. I would know - I wrote that section
I can can pull the studies if you want, but still...
http://dmd.aspetjournals.org/content/25/6/657.full
http://jat.oxfordjournals.org/content/26/7/430.full.pdf
Can someone interpret the indications of these studies (particularly with regard to my question)? Thanks.
endotropic
Bluelight Crew
That first study is a nice find, take a look at table 1 if you can. Basically in the first 48hr ~3% of the dose is recovered as d-amph, ~35% as d-meth, and minor amounts of unchanged selegiline, ephedrine isomers, and variable amounts of the hydroxylated amphetamines.
gearjammer
Greenlighter
I don't know if the TGA have scheduled d-dep, I imagine it is scheduled or covered under analogue laws, but it sounds like a viable alternative to Selegiline and dex for my all-encompassing ADHD if I can come across it. My depression is a direct result of my inability to concentrate on anything for more than 5 minutes. Watching The Wedding Singer in a splendid Nautica Competition vest. Peace.
Jabberwocky
Frumious Bandersnatch
even the wiki doesn't list whether it's scheduled or what.. I'd considered getting some a few yrs ago, but the concern of "prodrug to m.amp" stopped me; It's certainly not an analogue as far as I can tell, but prodrugs have still been targetted iirc.
So if D-deprenyl produces dependence, can it be assumed that the l-methamp produced by L-deprenyl is sufficiently active. Like several milligrams?
ebola?
Bluelight Crew
not really. The l-isomer binds more weakly than d-meth at all types of transporters, and the amount produced via metabolism is comparatively small, so even with potentiation by the selegiline, it could border on inactive.
ebola
Katuskoti
Greenlighter
I wonder if d-deprenyl would have any appreciable efficacy in preventing or reducing its metabolites' neurotoxicity? It seems possibly not.. However l-deprenyl does help counter 6-OHDA toxicity http://link.springer.com/article/10.1007/s004010050453
